POST informatif : la grosse lapine

----- http://www.has-sante.fr/portail/jcms/c_1036554/fr/ruconest?xtmc=&xtcr=57 -----


Ruconest -> Autant prendre l'ancien produit, c'est le même, même effet et BEAUCOUP moins cher!!!
RIEN DE NOUVEAUX si ce n'est le prix!

Relistor -> combien de mort?


Il existe des alternatives thérapeutiques médicamenteuses, notamment

---------- BERINERT et FIRAZYR. ----------


Le rapport efficacité / effets indésirables de cette spécialité est important.

Intérêt en termes de santé publique :
Le fardeau de santé publique représenté par les patients ayant des crises aiguës d’AOH (avec une carence en inhibiteur de la C1 estérase) est

---------- faible du fait de leur nombre restreint. ----------

L’amélioration de la prise en charge de cette maladie constitue un besoin de santé publique s’inscrivant dans le cadre du Plan national Maladies Rares 2010-2014.


D'après les résultats des essais cliniques,

---------- il n’est pas attendu d'impact pour la spécialité RUCONEST ----------

en termes populationnel sur la morbi-mortalité et la qualité de vie de ces patients.



La spécialité RUCONEST

---------- n’apporte pas de réponse supplémentaire ----------

au besoin identifié, ce d’autant que le produit, comme FIRAZYR et BERINERT,

---------- n’est pas auto-administrable par le patient ----------

et que son utilisation ne semble pas possible en situation d’urgence compte tenu du fait qu’elle est réservée aux patients ayant préalablement été testés négativement à une recherche d’anticorps.


En conséquence, en l’état actuel des connaissances,

---------- il n’est pas attendu d’intérêt de santé publique ----------

pour la spécialité RUCONEST dans cette indication.

Répondre

je le connais :
post d'Erasmus sur BIp..orama ^^

Répondre

Qu'est ce que le RUCONEST:
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-04/ruconest_-_ct-9842.pdf
u'est ce que l'AOH (angio-oedème héréditaire)? L’angio-œdème héréditaire (AOH) est une maladie génétique réputée rare, qui se caractérise par des épisodes récurrents de gonflements (œdèmes) situés au niveau du visage, des muqueuses et des organes internes, parfois susceptibles de mettre en jeu le pronostic vital (larynx).
Transmission autosomique (manque ou inefficacité de la protéine C1-INH sur le couple kallikréine-bradykinine; cette bradykinine, puissant vasodilatateur de très courte durée d'action qui provoque par cet afflux de sang dans les petits vaisseaux une ex-filtration provoquant l’œdème. A part cette cause génétique, on peut encore rencontrer, notamment chez des personnes âgées des causes auto-immunes et quelques très rares cas favorisés par des anti-hypertenseurs très à la mode, les ieca, qui empêchent l'inhibition enzymatique de la bradykinine, cas résolu très facilement par l'utilisation d'un sartan.

Prévalence en Europe:un pour 10.000 à 50.000.On en dénombre environ 50.000 en Europe et le nombre moyen de crises par an est de 8.5

C1-Inh:

1:
Une première réponse à la nécessité d'utiliser du lait de lapine pour fabriquer du C1-inh:
Il est impossible de fabriquer le C1-inh par la technologie recombinanteparce que l' Escherichia coli (l?organisme le plus couramment utilise à cette fin) ne présente pas la capacité eucaryotique de glycosyler les protéines; comme C1-inh est très fortement glycosylé, cette forme recombinante serait inefficace. Voilà.
2:
le C1-inh joue un rôle inhibiteur dans la réaction du complément.
L’activation de la cascade du complément peut provoquer des lésions cellulaires ; en conséquence, l’inhibition par le C1-inh peut éviter des dégâts importants par exemple dans une crise cardiaque ou les cellules nécrosées peuvent par libération de leurs déchets entraîner une cascade du complément qui a pour conséquence une activité phagocytaire sur le site lésé, une libération de peroxyde et d'autres produits nocifs pour les cellules avoisinantes, ce qui pourrait agraver la lésion originale. En fait le C1-inh agit à différents endroits de la chaîne, elle empêche la lectine d'agir en la fixant sur une protéase par une liaison mannane et bloque la transformation du complément entre la cascade C1r, C1s.
Ce qui fait que ce C1-Inh pourrait être proposé comme médicament complémentaire dans la crise cardiaque.
3:
le C1-inh a des propiétés anticoagulantes. Principalement en ayant des propriétés inhibitrices sur le facteur XIIA (facteur d'Haegeman) et le facteur XIA. Il possède aussi un rôle d’inhibiteur dans la fibrinolyse, le système des kinines, la kallicréine, la plasmine, la trypsine, la chymotrypsine. Paradoxalement, il aurait des propriétés protectrices en cas d'hémorragies graves, testées en préclinique sur le porc pour simuler des hémorragies graves sur champs de bataille. Il jouerait un rôle dans la prévention de l'IRI (ishémie reperfusion myocardique).
4:
peut aussi jouer un rôle dans le rejet de greffons après transplantation.



Le ruconest par rapport à la concurrence:
http://postimg.org/image/4t5zbxe3h/


Presentation de Pharming Group par Roth:
https://roth2.bluematrix.com/sellside/EmailDocViewer?encrypt=4aa1fbc9-b5ac-4a4a-95a3-cd3df2aa4418&mime=pdf&co=Roth2&id=morningcallmin@%20roth.com&source=mail&pdfFileExtension=.pdf


Actualité a court terme :
* En janvier 2014 ou plus tard par rapport à cette deadline, résultats définitifs sur AOH

http://www.clinicaltrials.gov/ct2/show/NCT01359969?term=ruconest&rank=2

* En Avril 2014 (au plus tard) approbation FDA :
et prime de 20 millions dollars (du partenaire) donc SALIX devrais payer 20 million de dollar à PHARMING, en cas d'accord AMM par FDA.
Plus une commission supplémentaire de 30-40% sur le prix de vente des produits vendus. Signe fort de confiance sur le dossier, pas d'avis consultatif de la FDA avant l'examen.
Les revenus sont prévus dans le premier semestre 2014 (KBC analyse)

"Santarus et Pharming cherchent l'approbation de commercialisation américaine de RUCONEST pour le traitement des crises aiguës angioedème chez les patients souffrant d'AOH. La demande de licence biologique (BLA) de dépôt pour RUCONEST est actuellement examinée par la US Food and Drug Administration (FDA) avec une réponse attendue d'ici le 16 Avril 2014. RUCONEST est approuvé en Europe pour le traitement de l'oedème angioneurotique aiguë chez les patients atteints d'AOH et est un médicament expérimental aux États-Unis qui a été accordé la désignation de médicament orphelin par la FDA. "
terme du contrat commercial avec Santarus:

Santarus remains committed to the collaboration with Pharming, with management highlighting Ruconest as a key
development pipeline component.
Collaboration terms
In September 2010 Pharming granted SNTS the exclusive rights to commercialize Ruconest in the U.S., Canada, and
Mexico, for the treatment of HAE and of other future indications.
• SNTS paid Pharming a $15 million upfront fee under the license agreement, followed by a $10 million
milestone in November 2012, with readout of successful Phase III data in HAE.
• Pharming is eligible for a $5 million milestone payment upon FDA accepting the BLA submission for review,
and a $20 million milestone based on the earlier of 1) first commercial sale of Ruconest in the U.S. or 2) 90
days following FDA approval.
In addition, Pharming is entitled to the following sales-based milestones:
• a $20 million milestone for calendar net sales >$300 million
• a $25 million milestone for calendar net sales >$500 million
SNTS pays Pharming a tiered supply price, based on % of net sales:
• 30% of net sales <$100 million
• 32% of net sales between $100 million and $250 million
• 34% of net sales between $250 million and $500 million
• 37% of net sales between $500 million and $750 million
• 40% of net sales >$750 million
Under the supply agreement, Pharming manufactures and supplies exclusively Ruconest to Santarus at the above
mentioned supply prices.


Historique : C'est la deuxième demande auprès de la FDA. Il y a déjà eu un premier refus en 2011
Terme du refus:
http://www.businesswire.com/news/home/20110227005080/en/Santarus-Pharming-Announce-Receipt-FDA-Refusal-File#.UtuztrVKFok


PHARM a une collaboration avec la chine :
http://seekingalpha.com/a/wuaa

Pharming's Ruconest Triggers Value Creation: Chinese Collaboration Joins U.S., EU Partners
Jul. 2, 2013 3:17 PM ET | This article is now exclusive for PRO subscribers.
About: PHGUF, Includes: SHTDF, SNTS, SWTUY
(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)

In the early hours of July 1, 2013 Dutch biotech company Pharming Group NV (OTC:PHGUF) announced that the company has entered into a strategic collaboration with Shanghai Institute of Pharmaceutical Industry (SIPI), a Sinopharm Company (OTCPK:SHTDF), for the development, manufacture and commercialization of new products based on the Pharming technology platform. In addition, Pharming has also granted SIPI an exclusive license to commercialise Ruconest in China.

Ruconest for Heredity Angioedema (HAE) has been developed for the treatment of acute attacks of HAE. HAE is a rare genetic deficiency of C1 inhibitor activity resulting in recurrent attacks..

China, July 01, 2013.

Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) and Shanghai Institute of Pharmaceutical Industry (“SIPI”), a Sinopharm Company , announced today that they have entered into a strategic collaboration for the development, manufacture and commercialisation of new products based on the Pharming technology platform. In addition, Pharming has also granted SIPI an exclusive license to commercialise Ruconest (conestat alfa) in China.


Under the terms of the agreement, Pharming will transfer the Pharming technology platform and manufacturing know- how to SIPI, such that joint global development for new products will take place at SIPI’s facilities in Shanghai and benefit from both the cost advantages of the Pharming platform and the competitive development and manufacturing costs structures at SIPI.

The first projects to be jointly developed at SIPI will be C1-inhibitor (conestat alfa) and Factor VIII. Under the agreement, SIPI will fund preclinical and manufacturing development.

Pharming will be responsible for obtaining Investigational New Drug (IND) applications from the US Food and Drug Administration (FDA) and/ or a Clinical Trial Application (CTA) from the European Medicines Agency (EMA); SIPI will be responsible for obtaining a Clinical Trial Permit (CTP) from the China Food and Drug Administration (CFDA) for each of the products.

SIPI will fund and be responsible for clinical development in China and Pharming for all clinical development outside of China. Both parties will, wherever possible, coordinate and combine clinical development activities.

To ensure world- wide commercialisation of the products developed and manufactured by SIPI, product development and manufacturing at SIPI will be implemented under Pharming’s fully ICH compliant quality assurance systems, and will be compliant with all CFDA, EMA and FDA regulatory guidelines.

SIPI will have commercialisation rights for the Chinese market for all new products developed; Pharming will retain global rights ex-China.

Over the past three decades, SIPI’s parent company, Sinopharm has established a number collaborative relationships and pharmaceutical joint ventures with companies from the US, Japan, and Europe

SIPI will pay Pharming €1.26 million upfront for the collaboration and a total of €0.84 million technology transfer related milestones associated with the implementation of the first technology transfer Ruconest (conestat alfa).

For every product developed by and manufactured, SIPI will pay Pharming a number of clinical and regulatory milestones. SIPI will supply Pharming on a cost plus basis for world- wide commercialisation. Pharming will pay SIPI 4% royalties on global sales (ex-China) and SIPI will pay Pharming 4% royalties on sales in China.


Until the technology transfer is completed and a Chinese marketing authorisation for SIPI produced conestat alfa has been granted, Pharming will supply SIPI with Ruconest® as an import drug for China, at a cost plus basis and 4% royalties and SIPI will pay Pharming a €0.3 million milestone upon receipt of a Ruconest® import license for China.

Sijmen De Vries, Chief Executive of Pharming commented:

This collaborative product development with SIPI, aimed at developing new recombinant products in a cost effective manner, is a significant strategic achievement and will drive the future growth of Pharming. The combination of SIPI’s vast resources and product development capabilities and Pharming’s platform will allow us to jointly develop a biological pipeline by engaging in future multiple product development activities and significantly increase the output of our platform. This collaboration represents an important source of future products, including for the fastest growing pharmaceutical market in the world; China

Dr. Weigen Lu, President of SIPI commented:

“Combining Pharming’s validated technology platform with SIPI’s capabilities in manufacturing, development, domestic regulatory and Sinopharm’s commercialisation network, we have created an opportunity to provide for China’s rapidly increasing need to domestically developed world- class quality biological medicines and to bringing to Chinese patients affordable biological medicines, and by supplying Pharming, we can become a global exporter of such domestically produced competitive world- class biological medicines.”


About SIPI/ Sinopharm

Shanghai Institute for Pharmaceutical Industry (SIPI) was established in 1957 and became part of Sinopharm in 2010. Within Sinopharm, SIPI is an integrated applied science institute with a long history and strong capability in Chinese pharmaceutical industry, SIPI discovers, develops medicines and transfers technologies. In addition, SIPI has a graduate school of Pharmacy.

China National Pharmaceutical Group Corporation, (Sinopharm) is the largest medical and healthcare group in China which is directly managed by State-owned Assets Supervision and Administration Commission of the State Council (SASAC), with the core businesses of distribution, logistics, retail, scientific research and manufacture of healthcare related products. Associated built on the basis of the four state-owned companies: China National Pharmaceutical (Group) Corporation, China National Pharmaceutical Industry Corporation, China National Pharmaceutical Foreign Trade Corporation and China National Medical Equipment Industry Corporation, Sinopharm was established in 1998. In 2003, China National Group Corporation of Traditional & Herbal Medicine joined Sinopharm. In 2009, Sinopharm restructured with China National Bio-tech Group (CNBG). As well as in 2010, Shanghai Institute of Pharmaceutical Industry (SIPI) and China National Service Corporation for Chinese Personnel Working Abroad (CNSC) joined Sinopharm. So far, Sinopharm owns 10 wholly owned or holding subsidiaries, and 5 listed companies including Sinopharm Group Co., Ltd. (01099.HK), China National Medicines Co., Ltd. (600511.SH), Beijing Tiantan Biological Products Co., Ltd. (600161.SH), Shyndec Pharmaceutical Co., Ltd. (600420.SH) and Shenzhen Accord Pharmaceutical Co., Ltd. (200028.SZ). The sales revenue of Sinopharm exceeded RMB 160 billion in 2012. It is the only Chinese pharmaceutical company whose sales revenue exceeds RMB 100 billion.
Sinopharm is aiming to be an international pharmaceutical and healthcare group which covering the whole industrial chain and can give strong impetus to the industry as well as the first Chinese pharmaceutical company of the Global Top 500 Corporations during the period of "the 12th Five-Year-Plan".


About Factor VIII and Haemophilia A

Haemophilia A is an X chromosome linked hereditary disorder caused by defects in the Factor VIII (FVIII) gene that lead to lower levels of the functional FVIII protein. Lack of functional FVIII diminishes the body’s clotting ability, which in turn can lead to damaging or fatal bleeding episodes. The global rhFVIII market was estimated to worth US$3.8 billion in 2009, with 90% of sales in the developed markets and very high unmet medical needs in the developing markets, such as China. In addition, only approximately 50% of the world-wide estimated haemophilia market can currently be supplied with appropriate FVIII therapy. Hence, there is still a high unmet medical need in this field with an estimated total market potential of US$10 billion.

Message complété le 21/02/2014 17:15:54 par son auteur.

PHARM vient de recevoir une autorisation pour l'ISRAEL:
source: http://www.pharming.com/

Pharming’s Partner, MegaPharm, Receive Marketing Authorisation For Ruconest® In Israel And Full Reimbursement

Leiden, The Netherlands, 15 January 2014. Biotech company Pharming Group NV (“Pharming”) (NYSE Euronext: PHARM) today announced that its partner, MegaPharm Ltd (MegaPharm), a privately owned Israeli pharmaceutical company, has received marketing approval for RUCONEST® (recombinant human C1 inhibitor) in Israel. The indication as approved is for the treatment of acute angioedema attacks in adults with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency. Alongside, Ruconest was approved by the reimbursement committee, to be added on the Israel Health basket with no extra costs.

Under the agreement, MegaPharm will purchase its commercial supply of RUCONEST from Pharming at a supply price based on a percentage of net sales. The number of HAE patients in Israel is estimated at approximately 250. MegaPharm anticipate launching RUCONEST during Q1 of this year.

Sijmen de Vries, CEO of Pharming, commented: "MegaPharm is a strong commercialization partner for us and has a proven track record in this region with a strong presence in the immunology therapeutic area. We are looking forward to providing HAE patients in Israel with a new and innovative treatment.”

About RUCONEST and Hereditary Angiodema
RUCONEST (INN conestat alfa) is a recombinant version of the human protein C1 esterase inhibitor, and is produced with Pharming's proprietary transgenic technology. RUCONEST is approved in Europe for the treatment of acute angioedema attacks in patients with HAE, a genetic disorder in which the patient is deficient in or lacks a functional plasma protein C1 esterase inhibitor, resulting in unpredictable and debilitating episodes of intense swelling. The swelling may occur in one or more anatomical areas, including the extremities, face, trunk, genitals, abdomen and upper airway. The frequency and severity of HAE attacks vary and are most serious when they involve laryngeal edema, which can close the upper airway and cause death by asphyxiation. According to the U.S. Hereditary Angioedema Association, epidemiological estimates for HAE range from one in 10,000 to one in 50,000 individuals. RUCONEST is an investigational drug in the U.S. and has been granted orphan drug designation by the FDA both for the treatment of acute attacks of HAE and for prophylactic treatment of HAE.

About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum. RUCONEST® is partnered with Salix Inc. (NASDAQ: SLXP) in North America and a Biologics License Application (BLA) for RUCONEST® is under review by the U.S. Food and Drug Administration. The product is also being evaluated for various follow-on indications. Pharming has a unique GMP compliant, validated platform for the production of recombinant human proteins that has proven capable of producing industrial volumes of high quality recombinant human protein in a more economical way compared to current cell based technologies. In July 2013, the Platform was partnered with Shanghai Institute for Pharmaceutical Industry (SIPI), a Sinopharm Company, for joint global development of new products. Pre- clinical development and manufacturing will take place at SIPI and are funded by SIPI. Pharming and SIPI initially plan to utilise this platform for the development of rhFVIII for the treatment of Haemophilia A. Additional information is available on the Pharming website, www.pharming.com.

About MegaPharm
MegaPharm Ltd. is one of the leading private biotech, pharmaceutical and medical nutrition marketing companies in Israel with a strong biotech orientation, exclusively representing a number of major American and European pharmaceutical companies. MegaPharm has demonstrated dynamic sales growth by developing a strong company presence and expertise in select therapeutic areas, and diversified segments of the healthcare business. For more information see www.megapharm.co.il.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.


lien ISRAEL FDA :
FDA Harmonization Project – Aligning Standards


One of the U.S.-Israel Science and Technology Foundation’s (USISTF) greatest successes in its mission to increase scientific development and strengthen economic relations is the U.S. Food and Drug Administration (FDA) Harmonization Project. The project brought about the alignment of American and Israeli standards in the areas as Good Clinical Practices (GCP), Good Manufacturing Practices (GMP), and Good Laboratory Practices (GLP).

In 1996, the USISTF provided $100,000 in funding to train over four hundred Israeli medical professional at the Ministry of Health. USISTF recognized the economic and social rewards of a simpler, more efficient clinical trials process. Israel has been a favored site for clinical studies, owing to its diverse population base, loyalty to a single HMO and relative ease of patient tracking. Historically, clinical studies in Israel have proven to be highly cost-effective, with high participant recruitment rates and much lower rate of patient drop out. Moreover, Israel ranks first in the world in several therapeutic areas and boasts a high quality medical environment.
Thus, increasing the number of clinical studies conducted by U.S. pharmaceutical companies in Israel would create a clear benefit to both nations.

In 1997, the Food and Drug Administration granted Israel recognition as a site for complete data acceptance for clinical studies with trials conducted for new drugs and medical devices in Israel. Israel's popularity as a site for clinical studies, particularly by U.S. multi-national companies, has grown exponentially since then. The USISTF’s investment in regulatory harmonization was a key element causing a boom of activity within the clinical trials industry; from a starting point of $15 million in net revenues in 1994, it had matured into a $300 million industry by 2005.

The Foundation's FDA Harmonization Project has compellingly demonstrated the mutual benefit, in terms of health and economic welfare, which the U.S. and Israel can derive from collaboration between their governments, industry, and research institutions. The opportunities and future potential of combined U.S. and Israeli endeavors in this particular industry are undoubtedly as great.


**Ruconest pris en charge en Hongrie:
http://www.ihs.com/products/global-insight/industry-economic-report?ID =1065985179


Le RUCONEST a un rapport cout-utilité supérieur a ses concurrents :

Source: http://scibite.com/site/library/2013_11/1/0/24278067.html

Kawalec P et al Postepy Alergol Dermatol. 2013 juin; 30 (3) :152-158. Epub 2013 le 20 juin
Conclusions de l'analyse : L'administration de Ruconest (R) dans l'angio-œdème attaques mortelles aiguës est économiquement justifiée du point de vue du payeur polonais de la santé, les résultats en baisse des coûts et est caractérisée par une probabilité plus élevée de coût-utilité comparaison avec Berinert (R)

* Le marché :

marché pour OAH aiguës est d'environ $ 230m en 2013 + 47 % par rapport à 2012,
marché US estimé à 370 millions de dollars + 13 % par rapport à 2012)

A noter que le RUCONEST est évalué sur un marché total de 1 739M€, la part de marché à 35% et les ventes optimales sont estimées à 687M€.
La marge est de 16% en Europe et 25% au US (Bénéfice après déduction des dépenses et dépenses de marketing) correspond à la part des bénéfices de l'entreprise sur les revenus futurs).
Si accord FDA, une commission supplémentaire de 30-40% sur le prix de vente des produits vendus sera accordée.
A noter que le marché connait une croissance a deux chiffres

* PHARM : Une bio opéable....

avec une forte prime à la clé (Viropharma est le concurent de PHARMING)

DUBLIN et Exton, Pennsylvanie 11 Novembre 2013 / PRNewswire / -

- Shire plc ( LSE : SHP , NASDAQ: expéd ) et ViroPharma Incorporated ( NASDAQ: VPHM ) annoncent aujourd'hui que leurs conseils d' administration ont approuvé à l'unanimité , et les sociétés ont conclu un accord de fusion aux termes duquel Shire d'acquérir toutes les actions en circulation de la société sur les maladies rares ViroPharma pour 50 $ par action en numéraire , pour un montant total d'environ 4,2 milliards de dollars. Le prix de l'action de 50 $ par la transaction représente une prime de 27 % au cours de clôture de l'action de ViroPharma , le vendredi 8 Novembre 2013, le dernier jour de bourse avant l'annonce , et une prime de 64% à cours de l'action de ViroPharma de $ 30,47 le 12 Septembre , 2013.
4

- http://www.reuters.com/article/2013/11/07/us-santarus-offer-idUSBRE9A61 BT20131107
Notez raison achat de Santarus par Salix
(Reuters) - Salix Pharmaceuticals Ltd (SLXP.O) will buy Santarus Inc (SNTS.O) for about $2.6 billion to boost its portfolio of drugs with a complementary set of products from the specialty pharmaceutical company.

* Des analyses confiants sur le dossier PHARMING GROUP (liste non exhaustive) :

- FIRST BERLIN vise 0.70 dans une note de 19/11/2013 (dernière étude)
www.pharming.com/index.php?act=dl&file=PHARM_NA-2013-11-19_EN.pdf
- KBC vise 0.22 et passe a acheter (pas arrivé depuis très
longtemps)
http://translate.googleusercontent.com/translate_c?depth=1&hl=fr &prev=/search%3Fq%3Diex%2B.nl%26newwindow%3D1%26client%3Dfirefox-a%26hs%3DpQ y%26rls%3Dorg.mozilla:fr:official%26channel%3Drcs&rurl=translate.google.fr&a mp;sl=nl&u=http://www.iex.nl/Aandeel-Koers/96535/Pharming-Group/adviezen.asp x&usg=ALkJrhgFwBZwYoP9mpNR0msVs9qMyI3OYA

* Consensus actualisés:
abc bourse : obj 0,18 cts, analystes -, avis -
La tribune : obj 0,46 cts, analystes 2, avis acheter
Fortunéo : obj 0,46 cts, analystes 2, avis acheter
Boursorama : obj 0,46 cts, analystes 1, avis acheter
le figaro : obj 0,46 cts, analystes 2, avis acheter
Reuters : obj 0,60 cts, analystes -, avis acheter
Markets : obj 0,70 cts, analystes 5, avis divers
First Berlin : obj 0,70 cts
Zone bourse: obj 0,82 cts, analystes 3, avis acheter
4 traders : obj 0,82 cts, analystes 3, avis acheter
Keytrade Bank : obj 0,82 cts, -


* des résultats en constante amélioration depuis 4 ans et un prévisionnel intéressant

Perspectives et projections faites de l'année 2013 à 2016 :

Chiffre d'affaires (M €) 8.15 / 19.69 / 13.48 / 58.28
Y-o-y N.A. de croissance - 25.00 % /141,5% / -31,5% / 332,3%
EBIT (en M €) -5,99 / 3,30 / -3,90 / 39,37
Marge EBIT -73,4% / 16,8% / -28,9% / 67,5%
Le résultat net (en M €) -14,85 / -3,99 / 2,97 / 34,89
EPS (dilué) (€) -0,04 / 0,01 / -0,01 / 0,10
FCF (m €) -13,78 / -7,25 / 2,93 / 18,73
Ratio d'endettement net 320,6% / 215,0% / 264,4% / 54,6%
Liquidités (en M €) 19,84 / 22,77 / 23,43 / 47,06

Message complété le 21/02/2014 17:19:12 par son auteur.

Répondre